BCL2L1 and Thrombocytopenia: They reported a novel pharmacodynamic effect of navitoclax on peripheral thrombocytopenia and T-cell lymphopenia in treating lymphoid tumors owing to high affinity inhibitions of BCL-2 and BCL-XL proteins (Wilson et al., 2010).